A Nutrigenomic Approach to Non-Alcoholic Fatty Liver Disease

被引:50
|
作者
Dongiovanni, Paola [1 ]
Valenti, Luca [1 ,2 ]
机构
[1] Osped Policlin Milano, Fdn IRCCS Ca Granda, Internal Med & Metab Dis, I-20122 Milan, Italy
[2] Univ Milan, Dept Pathophysiol & Transplantat, I-20122 Milan, Italy
关键词
nonalcoholic fatty liver disease; nutrigenomics; dietary nutrients; genetic factors; GENOME-WIDE ASSOCIATION; DE-NOVO LIPOGENESIS; INSULIN-RESISTANCE; HEPATIC STEATOSIS; TRIGLYCERIDE LEVELS; GENETIC-VARIATION; ADIPOSE-TISSUE; CONFERS SUSCEPTIBILITY; EPIGENETIC REGULATION; I148M POLYMORPHISM;
D O I
10.3390/ijms18071534
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Following the epidemics of obesity due to the consumption of high-calorie diet and sedentary lifestyle, nonalcoholic fatty liver disease (NAFLD) is now the leading cause of liver disease in Western countries. NAFLD is epidemiologically associated with metabolic syndrome and insulin resistance, and in susceptible individuals it may progress to cirrhosis and hepatocellular carcinoma. Genetic factors play a key role in NAFLD predisposition by interacting with nutritional and other environmental factors. To date, there is no drug therapy for the treatment of NAFLD, and the main clinical recommendation is lifestyle modification. In the last years, nutrigenomics is promoting an increased understanding of how nutrition affects the switch from health to disease by altering the expression of an individual's genetic makeup. The present review tries to summarize the most recent data evidencing how the interactions between nutrients and genetic factors can influence NAFLD development. The final goal should be to develop tools to quantify these complex interactions. The definition of a "nutrigenomic risk score" for each individual may represent a novel therapeutic approach for the management of NAFLD patients.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] Non-alcoholic Fatty Liver Disease
    Tan, Hui-Hui
    Chang, Jason Pik-Eu
    [J]. PROCEEDINGS OF SINGAPORE HEALTHCARE, 2010, 19 (01) : 36 - 50
  • [2] Non-alcoholic fatty liver disease
    Angulo, P
    Lindor, KD
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2002, 17 : S186 - S190
  • [3] Non-alcoholic fatty liver disease
    Carreras, MP
    Tortajada, GC
    [J]. REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2005, 97 (05) : 377 - 377
  • [4] Non-alcoholic fatty liver disease
    Maurice, James
    Manousou, Pinelopi
    [J]. CLINICAL MEDICINE, 2018, 18 (03) : 245 - 250
  • [5] Non-alcoholic fatty liver disease
    Smith, Briohny W.
    Adams, Leon A.
    [J]. CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 2011, 48 (03) : 97 - 113
  • [6] Non-alcoholic fatty liver disease
    Neuschwander-Tetri, Brent A.
    [J]. BMC MEDICINE, 2017, 15
  • [7] Non-alcoholic fatty liver disease
    Powell, Elizabeth E.
    Wong, Vincent Wai-Sun
    Rinella, Mary
    [J]. LANCET, 2021, 397 (10290): : 2212 - 2224
  • [8] Non-alcoholic fatty liver disease
    Tuyama, Ana C.
    Chang, Charissa Y.
    [J]. JOURNAL OF DIABETES, 2012, 4 (03) : 266 - 280
  • [9] Non-alcoholic fatty liver disease
    Bjornsson, Einar
    Angulo, Paul
    [J]. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2007, 42 (09) : 1023 - 1030
  • [10] Non-alcoholic fatty liver disease
    Cua, IHY
    George, J
    [J]. HOSPITAL MEDICINE, 2005, 66 (02): : 106 - 111